Search Results

Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley

Pfizer plans to settle a lawsuit filed 12 years ago by distributors of Lipitor for $93 million. The pharma giant was accused of colluding with Ranbaxy Laboratories to delay generic versions of the drug.

11 July 2024: Gaelic Laboratories unveils its new website today, launching an upgraded and expanded laboratory technology base for advanced analytical testing, and a newly re-fitted Beta-Lactam manufacturing facility, using the latest state-of-the art technology.

Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival and progression-free survival compared to placebo for patients with limited-stage small cell lung cancer who had not progressed following standard-of-care concurrent chemoradiotherapy.

The Association for Diagnostics & Laboratory Medicine released the results of a survey that ADLM conducted to determine how the Food and Drug Administration’s final laboratory developed tests rule will impact patient access to essential tests.

Avantor, Inc. announced that Corey Walker has rejoined the company as President of Avantor’s Laboratory Solutions business, reporting to CEO Michael Stubblefield.

Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).

US BioTek Laboratories (“US BioTek”), a Clinical Laboratory Improvement Amendments (CLIA) and CAP accredited laboratory, announces the acquisition of Dallas, TX-based RealTime Laboratories (“RealTime”), a pioneer in the field of mycotoxin testing.

VolitionRx Limited, a multi-national epigenetics company, has issued a mid-year review to stockholders, ahead of its Annual Meeting of Stockholders to be held on July 2, 2024.

C2N Diagnostics, LLC, which provides exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health, has entered into a non-exclusive agreement with Mayo Clinic Laboratories, for inclusion of C2N’s Precivity tests in Mayo Clinic Laboratories’ test offerings to its clients.